GleamWall
中文EN

DYAI DYADIC INTERNATIONAL INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY13.0%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—

Margins

Gross margin17.9%
Operating margin-236.7%
Net margin-226.9%
FCF margin—
EBITDA margin—

Returns

ROE-47,256.0%
ROA-71.4%
ROIC (approx.)—
Asset turnover0.31x

Leverage & solvency

Liabilities / assets132.5%
Debt / equity—
Current ratio1.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$449,101$961,138$1.11M$565,526$1.16M$966,630$393,572$817,376
Cost of revenue$375,115$984,165$791,840$384,608$1.02M$613,591$297,658$352,819
Gross profit$73,986-$23,027$319,116$180,918$140,614$353,039$95,914$464,557
R&D expense$429,945$332,621$476,069$458,436$571,872$629,379$494,979$545,660
SG&A expense$1.45M$1.69M$1.76M$1.25M$1.48M$1.44M$1.60M$1.44M
Operating income-$1.81M-$2.05M-$1.90M-$1.54M-$1.93M-$1.73M-$2.00M-$1.53M
Income tax$0$0$0—————
Net income-$1.36M-$2.12M-$1.95M-$1.57M-$1.98M-$1.79M-$2.03M-$1.55M
EPS (basic)-0.04-0.06-0.05—-0.06-0.06-0.07—
EPS (diluted)-0.04-0.06-0.05—-0.06-0.06-0.07—
Weighted avg. shares (diluted)38.29M36.44M36.40M—34.08M30.10M29.89M—
Balance sheet
Cash & equivalents$3.93M$1.43M$4.25M$4.62M$5.83M$2.14M$5.06M$6.51M
Short-term investments$646,987$1.69M$1.36M$2.70M$3.10M$2.84M$2.31M$2.76M
Receivables$1.52M$1.30M$996,464$1.09M$916,574$715,317$221,719$237,027
Current assets$7.87M$6.41M$7.70M$9.90M$11.55M$7.41M$7.81M$9.83M
Total assets$7.93M$6.54M$7.81M$9.95M$11.67M$8.14M$7.89M$9.93M
Current liabilities$4.65M$3.88M$3.18M$3.69M$4.05M$3.66M$1.96M$2.45M
Total liabilities$10.51M$8.92M$8.22M$8.71M$9.07M$8.67M$6.97M$7.46M
Shareholders' equity-$2.58M-$2.39M-$407,732$1.23M$2.61M-$529,701$923,611$2.47M
Shares outstanding40.09M36.44M36.44M36.19M36.19M30.14M—29.84M
Cash flow statement
Operating cash flow-$1.48M-$1.82M-$1.96M-$1.77M-$1.85M-$130,015-$1.95M-$696,395
Investing cash flow$1.15M-$356,884$1.27M$468,159$93,442-$961,620$482,104$1.26M
Financing cash flow———-$1$4.94M$0$24,249$24,251
Stock-based compensation$141,829$144,372$139,299$192,339$172,352$340,462$225,030$274,808

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.